AI Article Synopsis
- The study aimed to explore how the anti-DR5 monoclonal antibody (mDRA-6) works together with the cancer drug adriamycin (Adr) to kill HL-60 cells, a type of leukemia cell.
- Researchers used various methods, including flow cytometry and microscopy, to analyze the effects of these treatments on the cells, observing changes like cell budding and DNA fragmentation.
- The findings showed that mDRA-6 and Adr together significantly enhance cell death and apoptosis in HL-60 cells, indicating a synergistic effect.
Article Abstract
Objective: To investigate synergistic killing effect of anti-human DR5 (death receptor 5 of TRAIL) monoclonal antibody (mDRA-6) and adriamycin(Adr) on HL-60 cells.
Methods: mDRA-6 was prepared by immunizing BALB/c mice with DR5 protein. DR5 expression on Adr-treated HL-60 cells was detected by flow cytometry. Morphologic changes of HL-60 cells were observed under fluorescence microscope. Cytotoxic and apoptotic effects of mDRA-6 and Adr on HL-60 cells were measured by MTT analysis. DNA fragmentation was detected by agarose gel electrophoresis.
Results: Adr induce DR5 expression on HL-60 cells. Cell budding, chromatin condensation and apoptotic body formation were observed in HL-60 cells treated by mDRA-6 and Adr. Death and apoptosis of these cells and DNA ladder were exhibited on agarose gel electrophoresis.
Conclusion: mDRA-6 and Adr have synergistic killing effect on HL-60 cells.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!